Bioton S.A.
ISIN: PLBIOTN00029 | Ticker: BIO | LEI: 259400I5R1L3OPCGII81
Country: Poland
BIOTON is an innovative Polish biotechnology company, which provides patients with safe and complete solutions for diabetes care. Bioton is an unquestionable leader on the Polish market, and in the world’s top eight commercial manufacturers of recombinant human insulin.
Bioton continuously invests in the development of Polish biotechnology. We are the first and only company in Poland which is able to fully translate its technology into commercial use.
Recombinant human insulin is an efficient and safe therapy for most people suffering from diabetes. We strive to become the provider of complete diabetes care solutions and the preferred choice for patients, doctors and the diabetes community.
1989
Served areaWorldwide
HeadquartersStarościńska 5, 02-516 Warszawa – Poland
| Line item in (pln) | 02.01.2019 | 01.01.2020 | 02.01.2020 | 01.01.2021 | 02.01.2021 | 01.01.2022 | 02.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|---|---|---|
| Assets | N/A | 885,079,000.00 | N/A | 867,107,000.00 | N/A | 848,127,000.00 | N/A | 810,326,000.00 |
| Noncurrent Assets | N/A | 747,620,000.00 | N/A | 715,819,000.00 | N/A | 673,399,000.00 | N/A | 657,255,000.00 |
| Property Plant And Equipment | N/A | 327,197,000.00 | N/A | 310,017,000.00 | N/A | 286,551,000.00 | N/A | 275,051,000.00 |
| Investment Property | N/A | 1,357,000.00 | N/A | 1,357,000.00 | N/A | 1,357,000.00 | N/A | 1,357,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 376,565,000.00 | N/A | 370,223,000.00 | N/A | 362,177,000.00 | N/A | 362,975,000.00 |
| Deferred Tax Assets | N/A | 35,315,000.00 | N/A | 27,541,000.00 | N/A | 5,508,000.00 | N/A | 2,228,000.00 |
| Current Assets | N/A | 137,459,000.00 | N/A | 151,288,000.00 | N/A | 174,728,000.00 | N/A | 153,071,000.00 |
| Inventories | N/A | 79,726,000.00 | N/A | 90,017,000.00 | N/A | 125,131,000.00 | N/A | 111,002,000.00 |
| Trade And Other Current Receivables | N/A | 48,528,000.00 | N/A | 37,893,000.00 | N/A | 39,108,000.00 | N/A | 31,403,000.00 |
| Current Prepaid Expenses | N/A | 2,028,000.00 | N/A | 860,000.00 | N/A | 1,086,000.00 | N/A | 1,324,000.00 |
| Current Tax Assets Current | N/A | N/A | N/A | 279,000.00 | N/A | 546,000.00 | N/A | 3,000.00 |
| Cash and cash equivalents | 7,745,000.00 | 7,177,000.00 | 7,177,000.00 | 22,239,000.00 | 22,239,000.00 | 8,857,000.00 | 8,857,000.00 | 9,339,000.00 |
| Equity And Liabilities | N/A | 885,079,000.00 | N/A | 867,107,000.00 | N/A | 848,127,000.00 | N/A | 810,326,000.00 |
| Equity | 712,792,000.00 | 582,000,000.00 | 585,321,000.00 | 619,645,000.00 | 619,646,000.00 | 604,514,000.00 | N/A | 606,060,000.00 |
| Issued Capital | N/A | 1,717,284,000.00 | N/A | 1,717,284,000.00 | N/A | 1,717,284,000.00 | N/A | 1,717,284,000.00 |
| Retained Earnings | N/A | -1,101,878,000.00 | N/A | -1,067,958,000.00 | N/A | -1,083,301,000.00 | N/A | -1,081,880,000.00 |
| Share Premium | N/A | 57,131,000.00 | N/A | 57,131,000.00 | N/A | 57,131,000.00 | N/A | 57,131,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 585,320,000.00 | N/A | 619,645,000.00 | N/A | 604,514,000.00 | N/A | 606,060,000.00 |
| Noncurrent Liabilities | N/A | 102,718,000.00 | N/A | 90,116,000.00 | N/A | 77,543,000.00 | N/A | 63,212,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 2,226,000.00 | N/A | 1,762,000.00 | N/A | 1,486,000.00 | N/A | 1,470,000.00 |
| Noncurrent Accruals And Noncurrent Deferred Income Including Noncurrent Contract Liabilities | N/A | N/A | N/A | N/A | N/A | 36,257,000.00 | N/A | 32,745,000.00 |
| Deferred Tax Liabilities | N/A | 162,000.00 | N/A | 0.00 | N/A | N/A | N/A | N/A |
| Other Noncurrent Financial Liabilities | N/A | N/A | N/A | 10,342,000.00 | N/A | 10,342,000.00 | N/A | 10,342,000.00 |
| Other Noncurrent Nonfinancial Liabilities | N/A | 10,382,000.00 | N/A | 10,342,000.00 | N/A | N/A | N/A | N/A |
| Current Liabilities | N/A | 197,041,000.00 | N/A | 157,346,000.00 | N/A | 166,070,000.00 | N/A | 141,054,000.00 |
| Current Provisions For Employee Benefits | N/A | N/A | N/A | 2,492,000.00 | N/A | 2,474,000.00 | N/A | 2,216,000.00 |
| Trade And Other Current Payables | N/A | 77,693,000.00 | N/A | 49,971,000.00 | N/A | 36,932,000.00 | N/A | 36,095,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | N/A | N/A | N/A | 44,885,000.00 | N/A | 44,932,000.00 |
| Current Tax Liabilities Current | N/A | 121,000.00 | N/A | 5,000.00 | N/A | 1,162,000.00 | N/A | 74,000.00 |
| Line item in (pln) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 202,032,000.00 | 221,788,000.00 | 163,034,000.00 | 233,159,000.00 |
| Other Income | 3,938,000.00 | 32,711,000.00 | 5,946,000.00 | 4,667,000.00 |
| Profit Loss From Operating Activities | 163,543,000.00 | 48,580,000.00 | 14,342,000.00 | 21,258,000.00 |
| Finance Income | 9,207,000.00 | 1,143,000.00 | N/A | N/A |
| Finance Costs | 7,765,000.00 | 8,112,000.00 | 6,011,000.00 | 16,306,000.00 |
| Profit Loss Before Tax | 162,101,000.00 | 41,611,000.00 | 8,331,000.00 | 4,952,000.00 |
| Income Tax Expense Continuing Operations | 35,409,000.00 | 7,691,000.00 | 5,449,000.00 | 3,531,000.00 |
| Profit Loss From Continuing Operations | -126,692,000.00 | 33,920,000.00 | 2,882,000.00 | 1,421,000.00 |
| Profit (loss) | -126,692,000.00 | 33,920,000.00 | 2,882,000.00 | 1,421,000.00 |
| Profit Loss Attributable To Owners Of Parent | -126,692,000.00 | 33,920,000.00 | 2,882,000.00 | 1,421,000.00 |
| Line item in (pln) | 01.01.2020 | 02.01.2019 | 01.01.2021 | 02.01.2020 | 01.01.2022 | 02.01.2021 | 01.01.2023 | 02.01.2022 |
|---|---|---|---|---|---|---|---|---|
| Profit (loss) | -126,692,000.00 | N/A | 33,920,000.00 | N/A | 2,882,000.00 | N/A | 1,421,000.00 | N/A |
| Adjustments For Income Tax Expense | 620,000.00 | N/A | 198,000.00 | N/A | 364,000.00 | N/A | 292,000.00 | N/A |
| Adjustments For Decrease Increase In Inventories | -1,943,000.00 | N/A | -10,290,000.00 | N/A | -35,115,000.00 | N/A | 14,130,000.00 | N/A |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | N/A | 8,067,000.00 | N/A | 5,113,000.00 | N/A | 3,160,000.00 | N/A |
| Adjustments For Increase Decrease In Trade Account Payable | 19,470,000.00 | N/A | -33,218,000.00 | N/A | N/A | N/A | N/A | N/A |
| Adjustments For Increase Decrease In Other Operating Payables | -1,498,000.00 | N/A | 8,067,000.00 | N/A | N/A | N/A | N/A | N/A |
| Adjustments For Depreciation And Amortisation Expense | 32,281,000.00 | N/A | 31,731,000.00 | N/A | 31,638,000.00 | N/A | 34,403,000.00 | N/A |
| Adjustments For Provisions | -33,050,000.00 | N/A | -694,000.00 | N/A | -128,000.00 | N/A | 139,000.00 | N/A |
| Adjustments For Unrealised Foreign Exchange Losses Gains | 531,000.00 | N/A | -1,361,000.00 | N/A | -198,000.00 | N/A | 3,020,000.00 | N/A |
| Other Adjustments For Which Cash Effects Are Investing Or Financing Cash Flow | 144,311,000.00 | N/A | -438,000.00 | N/A | -2,586,000.00 | N/A | 1,069,000.00 | N/A |
| Interest Paid Classified As Operating Activities | N/A | N/A | N/A | N/A | 4,785,000.00 | N/A | 7,270,000.00 | N/A |
| Interest Received Classified As Operating Activities | 4,892,000.00 | N/A | 4,735,000.00 | N/A | 4,785,000.00 | N/A | N/A | N/A |
| Income Taxes Paid Refund Classified As Operating Activities | 534,000.00 | N/A | 941,000.00 | N/A | -636,000.00 | N/A | -1,470,000.00 | N/A |
| Cash Flows From Used In Operating Activities | 46,708,000.00 | N/A | 41,949,000.00 | N/A | 5,522,000.00 | N/A | 56,082,000.00 | N/A |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | 158,000.00 | N/A | 14,000.00 | N/A | 8,608,000.00 | N/A | 478,000.00 | N/A |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | -53,457,000.00 | N/A | 4,682,000.00 | N/A | 12,892,000.00 | N/A | 29,578,000.00 | N/A |
| Cash Flows From Used In Investing Activities | -53,802,000.00 | N/A | -4,684,000.00 | N/A | -4,284,000.00 | N/A | -29,100,000.00 | N/A |
| Proceeds From Issuing Shares | N/A | N/A | 311,000.00 | N/A | N/A | N/A | N/A | N/A |
| Proceeds From Borrowings Classified As Financing Activities | N/A | N/A | N/A | N/A | 33,812,000.00 | N/A | 15,468,000.00 | N/A |
| Repayments Of Borrowings Classified As Financing Activities | -33,760,000.00 | N/A | 18,764,000.00 | N/A | 43,128,000.00 | N/A | 32,463,000.00 | N/A |
| Payments Of Lease Liabilities Classified As Financing Activities | -4,736,000.00 | N/A | 2,486,000.00 | N/A | 1,525,000.00 | N/A | 2,706,000.00 | N/A |
| Proceeds From Government Grants Classified As Financing Activities | N/A | N/A | 2,051,000.00 | N/A | N/A | N/A | N/A | N/A |
| Interest Paid Classified As Financing Activities | -6,412,000.00 | N/A | 3,315,000.00 | N/A | 3,780,000.00 | N/A | 6,798,000.00 | N/A |
| Cash Flows From Used In Financing Activities | 6,526,000.00 | N/A | -22,203,000.00 | N/A | -14,621,000.00 | N/A | -26,499,000.00 | N/A |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | -568,000.00 | N/A | 15,062,000.00 | N/A | -13,383,000.00 | N/A | 483,000.00 | N/A |
| Cash and cash equivalents | 7,177,000.00 | 7,745,000.00 | 22,239,000.00 | 7,177,000.00 | 8,857,000.00 | 22,239,000.00 | 9,339,000.00 | 8,857,000.00 |
Please note that some sums might not add up.
PLBIOTN00029
LEI259400I5R1L3OPCGII81
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.